ThomasJGergelMD

Radiation Oncology • Sayre, PA

Physician

Join to view full profile

Dr. Gergel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gergel's full profile

Already have an account?

Office
1 Guthrie Sq
Sayre, PA 18840
Phone+1 570-887-4048

Fax+1 570-887-5166

Education & Training

University at BuffaloResidency, Radiation Oncology, 1999 - 2003
Adventist Hinsdale HospitalInternship, Transitional Year, 1998 - 1999
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1998

Certifications & Licensure

NY State Medical License 1999 - 2025
PA State Medical License 2003 - 2024
IL State Medical License 1998 - 2001
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

75 citations
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTC...
Ethan Basch, Stephanie L. Pugh, Amylou C. Dueck, Sandra A. Mitchell, Lawrence Berk
International Journal of Radiation Oncology, Biology, Physics. 2017-06-01
24 citations
A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of...
Shannon Fogh, Snehal Deshmukh, Lawrence Berk, Amylou C. Dueck, Kevin S. Roof
International Journal of Radiation Oncology, Biology, Physics. 2017-03-15
25 citations
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Scott Turner, Thomas Gergel, Hueizhi Wu, Michel Lacroix, Steven A. Toms
World Journal of Surgical Oncology. 2014-05-22